CRIS Current Research Information System

BARTESAGHI, RENATA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.765
AS - Asia 4.630
EU - Europa 3.420
AF - Africa 433
SA - Sud America 231
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.486
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.678
SG - Singapore 1.453
CN - Cina 1.149
VN - Vietnam 1.087
IT - Italia 919
GB - Regno Unito 683
DE - Germania 467
SE - Svezia 318
HK - Hong Kong 300
FR - Francia 188
IN - India 180
BR - Brasile 154
NL - Olanda 132
TG - Togo 129
RU - Federazione Russa 128
UA - Ucraina 128
IE - Irlanda 114
CI - Costa d'Avorio 95
BD - Bangladesh 91
ZA - Sudafrica 84
JP - Giappone 76
KR - Corea 72
CH - Svizzera 65
SC - Seychelles 63
FI - Finlandia 61
JO - Giordania 47
BG - Bulgaria 44
EE - Estonia 43
CA - Canada 42
AR - Argentina 34
PH - Filippine 34
BE - Belgio 31
NG - Nigeria 31
TR - Turchia 24
AT - Austria 22
MX - Messico 22
TH - Thailandia 20
IR - Iran 17
EC - Ecuador 14
PL - Polonia 14
GR - Grecia 13
ID - Indonesia 13
ES - Italia 12
IQ - Iraq 12
TW - Taiwan 11
KE - Kenya 9
SA - Arabia Saudita 9
CO - Colombia 8
JM - Giamaica 8
CL - Cile 7
LT - Lituania 7
MY - Malesia 7
AE - Emirati Arabi Uniti 5
AU - Australia 5
LB - Libano 5
PY - Paraguay 5
RO - Romania 5
ET - Etiopia 4
HR - Croazia 4
MA - Marocco 4
PK - Pakistan 4
VE - Venezuela 4
DZ - Algeria 3
MD - Moldavia 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BB - Barbados 2
BS - Bahamas 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
HU - Ungheria 2
NP - Nepal 2
PE - Perù 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AI - Anguilla 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
EG - Egitto 1
GA - Gabon 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
KG - Kirghizistan 1
LV - Lettonia 1
MF - Saint Martin 1
Totale 14.477
Salva come PNG Salva come JPEG
Città #
Singapore 1.043
Southend 581
Fairfield 565
Ashburn 545
Chandler 512
Santa Clara 345
Bologna 316
Hong Kong 283
Houston 279
Woodbridge 266
Wilmington 262
San Jose 254
Seattle 252
Ho Chi Minh City 234
Hanoi 226
Ann Arbor 211
Cambridge 201
Hefei 189
Dong Ket 153
Beijing 149
Princeton 147
Lomé 129
Dublin 113
Boardman 106
Abidjan 95
Council Bluffs 81
Jacksonville 80
Frankfurt am Main 77
Los Angeles 71
Lauterbourg 66
Nanjing 60
Westminster 59
New York 57
Seoul 57
Tokyo 57
Bern 56
Buffalo 53
Padova 53
Falls Church 52
Turin 52
Helsinki 50
Milan 48
Amman 46
Berlin 43
Sofia 43
Dallas 42
Redmond 36
San Diego 36
Shenyang 34
Guangzhou 31
Da Nang 29
Brussels 28
Munich 28
Abeokuta 27
Rome 26
Saint Petersburg 26
Tianjin 26
Johannesburg 25
Shanghai 25
Jinan 24
Rimini 24
Chicago 23
Haiphong 23
Nanchang 23
Hebei 21
Bengaluru 20
Redondo Beach 20
Changsha 19
São Paulo 19
Amsterdam 18
Dearborn 16
Mülheim 16
The Dalles 16
Redwood City 15
Toronto 15
Zhengzhou 15
Des Moines 14
Florence 14
Hải Dương 14
Orem 14
Phoenix 14
Wuhan 14
London 13
Taizhou 13
Mahé 12
Naples 12
Trento 12
Vienna 12
Bremen 11
Ardabil 10
Bolzano 10
Bristol 10
Ha Long 10
Mexico City 10
Norwalk 10
Vũng Tàu 10
Biên Hòa 9
Falkenstein 9
Nairobi 9
Olalla 9
Totale 9.638
Salva come PNG Salva come JPEG
Nome #
CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder 335
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome 310
A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS 308
Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders 274
Impaired brain mitochondrial bioenergetics in the ts65dn mouse model of down syndrome is restored by neonatal treatment with the polyphenol 7,8-dihydroxyflavone 258
Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse 255
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder 245
Obstructive sleep apneas naturally occur in mice during REM sleep and are highly prevalent in a mouse model of Down syndrome 240
Abnormal development of the inferior temporal region in fetuses with Down Syndrome 238
Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome 229
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome 227
Early appearance of dendritic alterations in neocortical pyramidal neurons of the Ts65Dn model of Down syndrome 221
Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome 220
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? 218
Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells. 216
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells 216
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome 215
The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for down syndrome. 215
Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome 213
APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. 207
Neurochemical correlates of nicotine neurotoxicity on rat habenulo-interpeduncular cholinergic neurons. 206
Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder 205
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome 205
Neuroanatomical Alterations in Higher-Order Thalamic Nuclei of Fetuses With Down Syndrome 205
APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. 199
Postnatal neurogenesis in the dentate gyrus of the guinea pig 198
Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. 198
Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome 197
Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice 197
SNX27, a protein involved in down syndrome, regulates GPR17 trafficking and oligodendrocyte differentiation 188
Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. 187
Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn Mouse, an animal model for Down syndrome. 186
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome 185
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome 183
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome 183
Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome. 182
Reversal of neurodevelopmental impairment and cognitive enhancement by pharmacological intervention with the polyphenol polydatin in a Down syndrome model 181
Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome 181
Topographic activation of the medial entorhinal cortex by presubicular commissural projections. 180
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. 179
Sex differences in the stereological parameters of the hippocampal dentate gyrus of the guinea pig before puberty 178
Sex differences in the hilar mossy cells of the guinea-pig before puberty. 176
Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression 170
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome 170
Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period. 169
Parallel activation of field CA2 and dentate gyrus by synaptically elicited perforant path volleys. 168
Timing of therapies for downsyndrome: The sooner, the better 166
Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. 165
Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat. 164
Effect of early isolation on signal transfer in the entorhinal cortex-dentate-hippocampal system 163
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. 162
CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/GSK-3{beta}/{beta}-catenin signaling 158
Cellularity Defects Are Not Ubiquitous in the Brains of Fetuses With Down Syndrome 157
Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome. 157
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome 155
Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation. 153
Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. 151
Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood 147
Is it possible to improve neurodevelopmental abnormalities in Down syndrome? 143
Dendritic phenotype and proliferation potency in the hippocampal dentate gyrus of the Ts66Yah model of Down syndrome 138
Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig. 138
Postnatal neurogenesis in the hippocampal dentate gyrus and subventricular zone of the Goettingen minipig. 136
The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives 135
Targeting APP/AICD in Down syndrome 131
null 130
Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome 128
Neurogenesis impairment: An early developmental defect in Down syndrome 127
Effects of early environment on field CA2 pyramidal neurons in the guinea-pig 125
Input-output relations in the entorhinal cortex-dentate-hippocampal system: evidence for a non-linear transfer of signals. 121
Epigallocatechin-3-gallate: Linking the neurogenesis, hippocampus, and Down syndrome 120
Effect of early isolation on the synaptic function in the dentate gyrus and field CA1 of the guinea pig. 117
Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down sindrome 117
New perspectives for the rescue of cognitive disability in down syndrome 103
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. 102
null 100
null 97
Advocating for increased awareness and research on Down syndrome 95
null 83
Sex differences in the hippocampal dentate gyrus of the guinea-pig before puberty 78
“Analisi dell’espressione genica in ippocampi di topi Ts65Dn sottoposti a trattamento adolescenziale con il BDNF-mimetico 7,8 diidrossiflavone” 75
“Administration of the BDNF mimetic 7,8-Dihydroxyflavone during adolescence rescues neuron maturation and improves hippocampus- dependent memory in the Ts65Dn mouse model of Down syndrome”. 70
“Il trattamento adolescenziale con il BDNF mimetico 7,8-diidrossiflavone influenza la metilazione del DNA nell'ippocampo del modello Ts65Dn di sindrome di Down” 63
“Effects of 7,8-dihydroxyflavone treatment on DNA methylation profiles of adolescent Ts65Dn mice hippocampus” 59
“Trattamento adolescenziale con il BDNF mimetico 7,8- diidrossiflavone: una strategia utile per migliorare lo sviluppo della fascia dentata ippocampica nel modello Ts65Dn di sindrome di Down”. 56
Effects of early environment on pyramidal neuron morphology in field CA1 of the guinea-pig 54
“Adolescence represents an important window of opportunity for the rescue of dendritic pathology with a BDNF mimetic in a mouse model of Down syndrome” 52
“Early pharmacotherapies for the rescue of intellectual disability in Down syndrome” 52
“Il trattamento con il polifenolo Polidatina migliora lo sviluppo cerebrale e la memoria ippocampo-dipendente nel topo Ts65Dn, modello di sindrome di Down” 48
Sex differences in the hilar mossy cells of the guinea-pig before puberty 48
Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: Implication for a survival role of nitric oxide 47
Effects of early isolation on layer II neurons in the entorhinal cortex of the guinea pig 34
Totale 14.736
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.223
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.223
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.366 82 55 92 84 145 94 81 80 57 93 250 253
2022/20231.896 171 364 108 253 111 151 56 84 283 29 137 149
2023/2024489 29 83 29 50 38 100 14 22 8 36 49 31
2024/20252.091 118 214 143 168 421 120 149 87 40 159 100 372
2025/20264.856 394 401 374 384 573 345 456 226 951 351 232 169
2026/2027133 133 0 0 0 0 0 0 0 0 0 0 0
Totale 14.736